Dysfunction of Sexual and Accessory Sex Organs

  • Sanjeev Kelkar


The issue of sexual dysfunction in diabetes is not limited to purveying prescriptions for drugs that are of help in this situation. Sex is one of the deepest drives of human existence and has many layers and concerns which need a much deeper understanding of this issue, much of which is beyond prescription. The understanding of nondrug issues is also essential to deal with those not infrequent unsatisfactory results after drug treatment. The need for a humanistic, emphatic, and supportive understanding to develop in dealing with female sexuality is profound and deeply rooted in the psyche developed over millions of generations. To cause a change is necessary in today’s times which incidentally will lead to an equally profound change in the treating physicians themselves. This chapter may be read from this perspective.


  1. 1.
    Maria ida Maiorino, Giuseppe Bellastella, Katherine Esposito, Diabetes, metabolic syndrome and obesity: targets and therapy open access to scientific and medical research, 4th Match 2014.
  2. 2.
    Guyton & Hall–Textbook of medical physiology. 11th ed. Pennsylvania: Elsevier Inc. International edition. ISBN 0-8089-2317-X; 2006.Google Scholar
  3. 3.
    Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol. 2005;47(1):80–5; discussion 85–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Bortolotti A, Fedele D, Chatenoud L, et al. Cigarette smoking: a risk factor for erectile dysfunction in diabetics. Eur Urol. 2001;40(4):392–6; discussion 397.PubMedCrossRefGoogle Scholar
  5. 5.
    Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology. 2004;64(6):1196–201.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosen RC, Wing RR, Schneider S, et al. Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the look AHEAD trial. J Sex Med. 2009;6(5):1414–22.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl. 1997;1:47–51.PubMedGoogle Scholar
  8. 8.
    Foresta C, Caretta N, Corona G, et al. Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. Int J Androl. 2009;32(3):198–211.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheitlin MD. Erectile dysfunction: the earliest sign of generalized vascular disease? J Am Coll Cardiol. 2004;43(2):185–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin N Am. 2007;36(2):453–63.CrossRefGoogle Scholar
  11. 11.
    Nicolosi A, Moreira ED, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61(1):201–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Bohem I, Murad H, Raz I, Israel Diabetes Research Group (IDRG) Investigators. Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care. 2005;28(7):1739–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005;28(5):1201–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Esposito K, Ciotola M, Giugliano F, et al. Endothelial microparticles correlate with erectile dysfunction in diabetic men. Int J Impot Res. 2007;19(2):161–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Sáenz de Tejada I, Angulo J, Cellek S, et al. Pathophysiology of erectile dysfunction. J Sex Med. 2005;2(1):26–39.PubMedCrossRefGoogle Scholar
  16. 16.
    Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction in men. Clin Pharmacol Ther. 2011;90(1):169–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complicat. 2011;25(2):129–36.PubMedCrossRefGoogle Scholar
  18. 18.
    Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6(5):1232–47.PubMedCrossRefGoogle Scholar
  19. 19.
    Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(11):5462–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):911–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261–70. [PubMed: 15071551].PubMedCrossRefGoogle Scholar
  22. 22.
    Bellastella G, Maiorino MI, Olita L, De Bellis A, Giugliano D, Esposito K. Anti-pituitary antibodies and hypogonadotropic hypogonadism in type 2 diabetes: in search of a role. Diabetes Care. 2013;36(8):e116–7.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Tirabassi G, Gioia A, Giovannini L, Boscaro M, Corona G, Carpi A, Maggi M, Balercia G. Testosterone and cardiovascular risk. Intern Emerg Med. 2013;8:S65–9. [PubMed: 23475207].PubMedCrossRefGoogle Scholar
  24. 24.
    Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217:R47–71. [PubMed: 23549841.PubMedCrossRefGoogle Scholar
  25. 25.
    Carson CC 3rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012;9:54–67. [PubMed: 21676183].PubMedCrossRefGoogle Scholar
  26. 26.
    Deenadayalu V, Puttabyatappa Y, Liu AT, Stallone JN, White RE. Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Phys. 2012;302:H115–23.Google Scholar
  27. 27.
    Cairrão E, Santos-Silva AJ, Verde I. PKG is involved in testosterone-induced vasorelaxation of human umbilical artery. Eur J Pharmacol. 2010;640:94–101. [PubMed: 20444426].PubMedCrossRefGoogle Scholar
  28. 28.
    Campelo AE, Cutini PH, Massheimer VL. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol. 2012;213:77–87. [PubMed: 22281525].PubMedCrossRefGoogle Scholar
  29. 29.
    Chavoshan B, Fournier M, Lewis MI, Porszasz J, Storer TW, Da X, Rambod M, Casaburi R. Testosterone and resistance training effects on muscle nitric oxide synthase isoforms in COPD men. Respir Med. 2012;106:269–75. [PubMed: 21843929].PubMedCrossRefGoogle Scholar
  30. 30.
    Goglia L, Tosi V, Sanchez AM, Flamini MI, Fu XD, Zullino S, Genazzani AR, Simoncini T. 2010 endothelial regulation of eNOS, PAI-1 and t-PA by testosterone and dihydrotestosterone in vitro and in vivo. Mol Hum Reprod. 2010;16:761–9. [PubMed: 20547636].PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Yu J, Akishita M, Eto M, Ogawa S, Son BK, Kato S, Ouchi Y, Okabe T. Androgen receptor dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. Endocrinology. 2010;151:1822–8. [PubMed: 20194727].PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Yu J, Akishita M, Eto M, Koizumi H, Hashimoto R, Ogawa S, Tanaka K, Ouchi Y, Okabe T. Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochem Biophys Res Commun. 2012;424:538–43. [PubMed: 22771325].PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Mancini A, Leone E, Festa R, Grande G, Silvestrini A, de Marinis L, Pontecorvi A, Maira G, Littarru GP, Meucci E. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl. 2008;29:622–9. [PubMed: 18641414].PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, Channer KS. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6. [PubMed: 15253956].PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669–75. [PubMed: 21709300].PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108:272–80. [PubMed: 17945484].PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis. 2003;37(suppl 2):S142–9. [PubMed: 12942389].PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol. 2012;227:3744–8. [PubMed: 22495883].PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–99. [PubMed: 16537739].PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230–6. [PubMed: 20038741].PubMedCrossRefGoogle Scholar
  41. 41.
    Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32:587–98. [PubMed: 19226407].PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK, Moses J. Hormone neurotransmitter interactions in the control of sexual behavior. Behav Brain Res. 1999;105:105–16. [PubMed: 10553694].PubMedCrossRefGoogle Scholar
  43. 43.
    Suzuki N, Sato Y, Hisasue SI, Kato R, Suzuki K, Tsukamato T. Effect of testosterone on intracavernosal pressure elicited with electrical stimulation of the medial preoptic area and cavernous nerve in male rats. J Androl. 2007;28:218–22. [PubMed: 16957136].PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology. 1999;140:1861–8. [PubMed: 10098525].PubMedCrossRefGoogle Scholar
  45. 45.
    Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2:759–70. [PubMed: 16422801].PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl. 2003;5:33–6. [PubMed: 12647000].PubMedGoogle Scholar
  47. 47.
    Iacono F, Prezioso D, Ruffo A, Illiano E, Romis L, Di Lauro G, Romeo G, Amato B. Testosterone deficiency causes penile fibrosis and organic erectile dysfunction in aging men. Evaluating association among age, TDS and ED. BMC Surg. 2012;12(suppl 1):S24. [PubMed: 23173727].PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Waldkirch E, Uckert S, Schultheiss D, Geismar U, Burns C, Scheller F, Jonas U, Becker A, Stief CG, Hedlund P. Non-genomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue. BJU Int. 2007;101:71–5. [PubMed: 17868421].PubMedGoogle Scholar
  49. 49.
    Han DH, Chae MR, Jung H, So I, Park JK, Lee SW. Effect of testosterone on potassium channel opening in human corporal smooth muscle cells. J Sex Med. 2008;5:822–32. [PubMed: 18208499].PubMedCrossRefGoogle Scholar
  50. 50.
    Yildiz O, Seyrek M, Irkilata HC, Yildirim I, Tahmaz L, Dayanc M. Testosterone might cause relaxation of human corpus cavernosum by potassium channel opening action. Urology. 2009;74:229–32. [PubMed: 19362348].PubMedCrossRefGoogle Scholar
  51. 51.
    Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol. 2003;58:632–8. [PubMed: 12699447].CrossRefGoogle Scholar
  52. 52.
    Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidence. Eur Urol. 2006;50:940–7. [PubMed: 16979814].PubMedCrossRefGoogle Scholar
  53. 53.
    Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. A critical analysis of the role of testosterone in erectile function. Eur Urol. 2014;65(1):99–112.PubMedCrossRefGoogle Scholar
  54. 54.
    Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. [PubMed: 23597181].PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7. [PubMed: 16339333].PubMedCrossRefGoogle Scholar
  56. 56.
    Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39. [PubMed: 17285783].PubMedCrossRefGoogle Scholar
  57. 57.
    Haring R, Teng Z, Xanthakis V, Coviello A, Sullivan L, Bhasin S, Murabito JM, Wallaschofski H, Vasan RS. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham heart study. Clin Endocrinol. 2013;78:629–34. [PubMed: 22901104].CrossRefGoogle Scholar
  58. 58.
    Kushiyama A, Tanaka K, Hara S, Kawazu S. Linking uric acid metabolism to diabetic complications. World J Diabetes. 2014;5:787–95. [PubMed: 25512781].PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Salem S, Mehrsai A, Heydari R, Pourmand G. Serum uric acid as a risk predictor for erectile dysfunction. J Sex Med. 2014;11:1118–24. [PubMed: 24621054].PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54–61. [PubMed: 8254833].PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Banks E, Joshy G, Abhayaratna WP, Kritharides L, Macdonald PS, Korda RJ, Chalmers JP. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med. 2013;10:e1001372. [PubMed: 23382654].PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Rigatti P, Montorsi F. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96:19M–23.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Wessells H, Sullivan CJ, Tsubota Y, Engel KL, Kim B, Olson NE, Thorner D, Chitaley K. Transcriptional profiling of human cavernosal endothelial cells reveals distinctive cell adhesion phenotype and role for claudin 11 in vascular barrier function. Physiol Genomics. 2009;39:100–8. [PubMed: 19622796].PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Lavoisier P, Proulx J, Courtois F, De Carufel FJ. Bulbocavernosus reflex: its validity as a diagnostic test of neurogenic impotence. Urol. 1989;141(2):311–4. PMID:2913351, Scholar
  65. 65.
    Dyck PJ, Thomas PK. Diabetic neuropathy. 2nd ed. Philadelphia: W B Saunders Company; 1999. p. 201–5.Google Scholar
  66. 66.
    Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of life style changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291(24):2978–84. Scholar
  67. 67.
    Giugliano D, Giugliano F, Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutr. 2006;9(8A):1118–20. Scholar
  68. 68.
    Esposito K, Giugliano F, Maiorino MI, Giugliano D. Dietary factors, Mediterranean diet and erectile dysfunction. J Sex Med. 2010;7(7):2338–45. Scholar
  69. 69.
    Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22(7):1208–12.PubMedCrossRefGoogle Scholar
  70. 70.
    Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol. 2006;50(1):134–40. Scholar
  71. 71.
    Stuckey BG, Jadzinsky MN, Murphy LJ, Montorsi F, Kadioglu A, Fraige F, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279–84.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281(5):421–6.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44(10):1296–301. Scholar
  74. 74.
    Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo controlled study. J Diabetes Complicat. 2004;18(4):205–10. Scholar
  75. 75.
    Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004;47(11):1914–23. Scholar
  76. 76.
    Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–83.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006;3(5):883–91. Scholar
  78. 78.
    Park HJ, Choi HK, Ahn TY, Park JK, Chung WS, Lee SW, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010;7(8):2842–50. Scholar
  79. 79.
    du Moon G, Yang DY, Lee CH, Ahn TY, Min KS, Park K, et al. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sex Med. 2011;8(7):2048–61. Scholar
  80. 80.
    Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65(12):1621–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14:545.PubMedCrossRefGoogle Scholar
  82. 82.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated urethral system for erection (MUSE) study group. N Engl J Med. 1997;336(1):1–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Buvat R, Fernando Y, Damaj B, Moncada I, Frank D, Burger M. Clinically significant approvement of erectile function following treatment with alprostadil cream (Vitaros®) in 1652 patients with erectile dysfunction. J Sex Med. 2012;9(suppl 5):384. abstract P-01-086.Google Scholar
  84. 84.
    Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68(2):386–91. Scholar
  85. 85.
    Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama A, Nijeholt GA, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol. 1998;81(6):889–94.PubMedCrossRefGoogle Scholar
  86. 86.
    Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res. 2001;13(6):317–21.PubMedCrossRefGoogle Scholar
  87. 87.
    Perimenis P, Konstantinopoulos A, Perimeni PP, Gyftopoulos K, Kartsanis G, Liatsikos E, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl. 2006;8(2):219–24. Scholar
  88. 88.
    Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802–15.PubMedCrossRefGoogle Scholar
  89. 89.
    Tal R, Mulhall JP. Intracavernosal injections and fibrosis: myth or reality? BJU Int. 2008;102(5):525–6. Scholar
  90. 90.
    Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR, Osborn DE. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med. 1991;8(10):964–7. 71.PubMedCrossRefGoogle Scholar
  91. 91.
    Sidi AA, Becher EF, Zhang G, Lewis JH. Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol. 1990;144(5):1154–6.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Carson CC. Penile prosthesis implantation: surgical implants in the era of oral medication. Urol Clin North Am. 2005;32(4):503–9. Scholar
  93. 93.
    Henry GD, Wilson SK. Updates in inflatable penile prostheses. Urol Clin North Am. 2007;34(4):535–47. Scholar
  94. 94.
    Chen Y, Dai Y, Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother. 2008;9(2):257–66. Scholar
  95. 95.
    Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006;8(6):675–84. Scholar
  96. 96.
    Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, McLeod DG. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol. 1992;147(2):386–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of follow up. J Urol. 2011;185(2):614–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Mulcahy JJ, Carson CC 3rd. Long-term infection rates in diabetic patients implanted with antibiotic-impregnated versus non impregnated inflatable penile prostheses: 7-year outcomes. Eur Urol. 2011;60(1):167–72. Scholar
  99. 99.
    Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med. 2012;9(1):259–64. Scholar
  100. 100.
    Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Dennerstein L, Randolph J, Taffe J, Dudley E, Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril. 2002;77(Suppl 4):S42–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762–74.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Abu Ali RM, Al Hajeri RM, Khader YS, Shegem NS, Ajlouni KM. Sexual dysfunction in Jordanian diabetic women. Diabetes Care. 2008;31(8):1580–1.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):179–84.PubMedCrossRefGoogle Scholar
  105. 105.
    Ogbera AO, Chinenye S, Akinlade A, Eregie A, Awobusuyi J. Frequency and correlates of sexual dysfunction in women with diabetes mellitus. J Sex Med. 2009;6(12):3401–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Eyada M, Atwa M. Sexual function in female patients with unstable angina or non-ST-elevation myocardial infarction. J Sex Med. 2007;4(5):1373–80.PubMedCrossRefGoogle Scholar
  107. 107.
    Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. Hypertension. 2006;24(12):2387–92.CrossRefGoogle Scholar
  108. 108.
    Krychman M, Millheiser LS. Sexual health issues in women with cancer. J Sex Med. 2013;10(Suppl 1):5–15.PubMedCrossRefGoogle Scholar
  109. 109.
    Peng YS, Chiang CK, Kao TW, et al. Sexual dysfunction in female hemodialysis patients: a multicenter study. Kidney Int. 2005;68(2):760–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007;369(9561):597–611.PubMedCrossRefGoogle Scholar
  111. 111.
    Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163(3):888–93.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Hotaling JM, Sarma AV, Patel DP, Braffett BH, Cleary PA, Feldman E, Herman WH, Martin CL, Jacobson AM, Wessells H, Pop-Busui R. Women with type 1 diabetes, for the diabetes control and complications trial/ epidemiology of diabetes interventions and complications research group. Diabetes Care. 2016;39:1587–93. Scholar
  113. 113.
    American Psychiatric Association. Appendix. Highlights of changes from DSM-IV to DSM-5. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  114. 114.
    Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Mauritas. 2009;63:116–8.Google Scholar
  115. 115.
    Rochester-Eyeguokan C, Meade L. A practical approach to managing hypoactive sexual desire disorder in women with diabetes. Diabetes Ther. 2017;8:991–8. Scholar
  116. 116.
    Tyrer G, Steel JM, Ewing DJ, Bancroft J, Warner P, Clarke BF. Sexual responsiveness in diabetic women. Diabetologia. 1983;24(3):166–71.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Enzlin P, Mathieu C, Vanderschueren D, Demyttenaere K. Diabetes mellitus and female sexuality: a review of 25 years’ research. Diabet Med. 1998;15(10):809–15.PubMedCrossRefGoogle Scholar
  118. 118.
    Veronelli A, Mauri C, Zecchini B, et al. Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk. A preliminary report. J Sex Med. 2009;6(6):1561–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Castellini G, Mannucci E, Mazzei C, et al. Sexual function in obese women with and without binge eating disorder. J Sex Med. 2010;7(12):3969–78.PubMedCrossRefGoogle Scholar
  120. 120.
    Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. Sexual dysfunction in women with the metabolic syndrome. Diabetes Care. 2005;28(3):756.PubMedCrossRefGoogle Scholar
  121. 121.
    Martelli V, Valisella S, Moscatiello S, et al. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012;9(2):434–41.PubMedCrossRefGoogle Scholar
  122. 122.
    Enzlin P, Rosen R, Wiegel M, DCCT/EDIC Research Group. et alSexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/EDIC study cohort. Diabetes Care 2009;32(5): 780–785.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Enzlin P, Mathieu C, Van Den Bruel A, Vanderschueren D, Demyttenaere K. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care. 2003;26(2):409–14.PubMedCrossRefGoogle Scholar
  124. 124.
    Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Curr Diabetes Rev. 2009;5(2):112–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Rockliffe-Fidler C, Kiemle G. Sexual function in diabetic women: a psychological perspective. Sex Relation Ther. 2003;18(2):143–59.CrossRefGoogle Scholar
  126. 126.
    Bargiota A, Dimitropoulos K, Tzortzis V, Koukoulis GN. Sexual dysfunction in diabetic women. Hormones (Athens). 2011;10(3):196–206.CrossRefGoogle Scholar
  127. 127.
    Meeking DR, Fosbury JA, Cummings MH. Sexual dysfunction and sexual health concerns in women with diabetes. Pract Diabet. 2013;30(8):327–31.CrossRefGoogle Scholar
  128. 128.
    Muniyappa R, Norton M, Dunn ME, Banerji MA. Diabetes and female sexual dysfunction: moving beyond “benign neglect”. Curr Diab Rep. 2005;5(3):230–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Berman JR, Berman LA, Toler SM, Gill J, Haughie S, Sildenafil Study Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol. 2003;170(6 Pt 1):2333–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Min K, Munarriz R, Kim NN, Goldstein I, Traish A. Effects of ovariectomy and estrogen and androgen treatment on sildenafil mediated changes in female genital blood flow and vaginal lubrication in the animal model. Am J Obstet Gynecol. 2002;187(5):1370–6.PubMedCrossRefGoogle Scholar
  131. 131.
    Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110:7–11.PubMedCrossRefGoogle Scholar
  132. 132.
    Miocic J, Car N, Metelko Z. Sexual dysfunction in women with diabetes mellitus. Diabetol Croat. 2008;37:35–42.Google Scholar
  133. 133.
    Feldhaus-Dahir M. The causes and prevalence of hypoactive sexual desire disorder: part I. Urol Nurs. 2009;29(4):259–60, 263.PubMedGoogle Scholar
  134. 134.
    Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61(2):160–73.PubMedCrossRefGoogle Scholar
  135. 135.
    Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s sexual health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92(1):114–28.PubMedCrossRefGoogle Scholar
  136. 136.
  137. 137.
    Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communication with patients on sexual health. Pharmacotherapy. 2013;33(4):411–21.PubMedCrossRefGoogle Scholar
  138. 138.
    Marcia Frellick, FDA Approves New Libido-Boosting Drug for Premenopausal Women - Medscape - Jun 21, 2019.Google Scholar
  139. 139.
    Condorelli RA, Vicari E, Calogero AE, La Vigneraby S. Male accessory gland inflammation prevalence in type 2 diabetic patients with symptoms possibly reflecting autonomic neuropathy. Asian J Androl. 2014;16:761–6.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Sanjeev Kelkar
    • 1
  1. 1.Independent Health ResearcherPuneIndia

Personalised recommendations